Inventera KRX:0007J0KOSDAQ
인벤테라 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Inventera reported revenue of ₩0m and an operating loss of ₩2.7bn. Inventera (인벤테라) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Nov 6 with 9 articles. The most common catalyst was tech & capacity (1). It was most often mentioned alongside LG Chem.
Filing signals Insider buying Clinical trial filing 4 quarters of losses Screener
Inventera at a glance from DART filings
- Results trend
- Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩2.7bn a loss again after the previous quarter.
- Ownership changes
- 2 5%-holder and insider ownership reports in the past 120 days (1 increases, 1 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Inventera today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Inventera stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Inventera quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩0m | – | −₩2.7bn | −₩2.5bn |
| Q2 2026 | ₩0m | – | −₩2.5bn | −₩2.3bn |
| Q3 2025 | ₩0m | – | −₩2.8bn | −₩2.6bn |
| Q2 2025 | ₩0m | – | −₩1.6bn | −₩1.4bn |
Inventera ranks #2043 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Inventera top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Inventera news Korean headlines
-
Inventerra signs contract with LG Chem to produce pancreaticobiliary MRI contrast raw material
6 more on this story · 5 outlets
- Inventerra signs contract with LG Chem for pancreaticobiliary MRI contrast agent API production이데일리 · Nov 6 09:53
- Inventerra signs contract with LG Chem for pancreaticobiliary MRI contrast agent API production이데일리 · Nov 6 09:54
- Inventra, LG Chem 'sign contract for contrast agent new drug raw material production'뉴시스경제 · Nov 6 10:52
- Invtera signs contract with LG Chem for API production of pancreaticobiliary contrast agent INV-003더바이오 · Nov 6 11:21
- Inventer signs API supply contract with LG Chem for 'pancreatic-biliary MRI contrast agent'이투데이 · Nov 6 11:34
- Inventerra signs pancreatic duct MRI contrast agent raw material contract with LG Chem글로벌경제신문 · Nov 6 16:37
-
Inventera signs joint research contract on next-generation ADC with U.S. UCSF
1 more on this story · 1 outlets
- Inventera and U.S. UCSF launch joint research on nanoplaform ADC이투데이 · Oct 28 14:35
-
MajorInventera co-develops next-generation ADC with U.S. UCSF; expands nanomedicine technology into cancer drugs
1 more on this story · 1 outlets
-
G2Zbio partners with Chinese pharma company; Inventera receives U.S. clinical green light
1 more on this story · 1 outlets
-
Inventera INV-002 adopts U.S. ingredient name Ferucadextran
2 more on this story · 2 outlets